# Vaxdyn, S. L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vaxdyn-s-l

- Industry: Pharmaceuticals
- Headquarters: Sevilla, Spain
- Website: www.vaxdyn.com
- Total disclosed funding: $13M
- Latest round: Series A (Sep 7, 2026)
- Investors on record: 3

## About

Based in Sevilla, Spain, Vaxdyn, S.L. is a biotechnology company Co-founded in 2011 by Michael J. McConnell & Pilar Perez Romero.  Dr. Juan José Infante serves as the company's Chief Executive Officer. The company develops vaccines targeting bacterial infections, including AcinetoVax for Acinetobacter baumannii and KapaVax for Pseudomonas aeruginosa and Klebsiella pneumoniae. In September 2026, Vaxdyn, S. L. raised EUR 11 million in series A funding  from Biovance Capital, European Innovation Council and Arcano Partners.
Vaxdyn develops vaccines targeting antibiotic-resistant infections, including AcinetoVax, aimed at Acinetobacter baumannii, and KapaVax, which targets Pseudomonas aeruginosa and Klebsiella pneumoniae. These products address critical healthcare needs globally, focusing on regions severely impacted by antibiotic resistance.

The company plans to use the September 2026 funding to begin Phase 1 clinical development of K-VAX for preventing infections associated with antibiotic-resistant bacteria.

## Funding rounds

- Series A, Sep 7, 2026, $13M — Arcano Partners, Biovance Capital, European Innovation Council
- Seed, Mar 8, 2021, $0.4M — Biovance Capital

## Investors

- Biovance Capital (https://capitalatlas.ai/funds/biovance-capital) — Seed, Series A
- Arcano Partners (https://capitalatlas.ai/funds/arcano-partners) — Series A
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series A